172 related articles for article (PubMed ID: 7551233)
1. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions.
Ulrich JT; Myers KR
Pharm Biotechnol; 1995; 6():495-524. PubMed ID: 7551233
[TBL] [Abstract][Full Text] [Related]
2. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.
Vandepapelière P; Horsmans Y; Moris P; Van Mechelen M; Janssens M; Koutsoukos M; Van Belle P; Clement F; Hanon E; Wettendorff M; Garçon N; Leroux-Roels G
Vaccine; 2008 Mar; 26(10):1375-86. PubMed ID: 18272264
[TBL] [Abstract][Full Text] [Related]
3. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines.
Baldridge JR; Crane RT
Methods; 1999 Sep; 19(1):103-7. PubMed ID: 10525445
[TBL] [Abstract][Full Text] [Related]
4. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results.
Cluff CW
Adv Exp Med Biol; 2010; 667():111-23. PubMed ID: 20665204
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529.
Evans JT; Cluff CW; Johnson DA; Lacy MJ; Persing DH; Baldridge JR
Expert Rev Vaccines; 2003 Apr; 2(2):219-29. PubMed ID: 12899573
[TBL] [Abstract][Full Text] [Related]
6. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems.
Garçon N; Van Mechelen M
Expert Rev Vaccines; 2011 Apr; 10(4):471-86. PubMed ID: 21506645
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of AS04.
Garçon N
Methods Mol Biol; 2010; 626():15-27. PubMed ID: 20099118
[TBL] [Abstract][Full Text] [Related]
8. Encapsulation of the immune potentiators MPL and RC529 in PLG microparticles enhances their potency.
Kazzaz J; Singh M; Ugozzoli M; Chesko J; Soenawan E; O'Hagan DT
J Control Release; 2006 Feb; 110(3):566-73. PubMed ID: 16360956
[TBL] [Abstract][Full Text] [Related]
9. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity.
Didierlaurent AM; Morel S; Lockman L; Giannini SL; Bisteau M; Carlsen H; Kielland A; Vosters O; Vanderheyde N; Schiavetti F; Larocque D; Van Mechelen M; Garçon N
J Immunol; 2009 Nov; 183(10):6186-97. PubMed ID: 19864596
[TBL] [Abstract][Full Text] [Related]
10. Development of a leishmaniasis vaccine: the importance of MPL.
Reed SG; Coler RN; Campos-Neto A
Expert Rev Vaccines; 2003 Apr; 2(2):239-52. PubMed ID: 12899575
[TBL] [Abstract][Full Text] [Related]
11. Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults.
Vandepapelière P; Rehermann B; Koutsoukos M; Moris P; Garçon N; Wettendorff M; Leroux-Roels G
Vaccine; 2005 Apr; 23(20):2591-601. PubMed ID: 15780441
[TBL] [Abstract][Full Text] [Related]
12. DNA immunization in combination with the immunostimulant monophosphoryl lipid a.
Lodmell DL; Ray NB; Ewalt LC
Methods Mol Med; 2000; 29():261-6. PubMed ID: 21374326
[TBL] [Abstract][Full Text] [Related]
13. Safety evaluation of a new allergy vaccine containing the adjuvant monophosphoryl lipid A (MPL) for the treatment of grass pollen allergy.
Baldrick P; Richardson D; Wheeler AW; Woroniecki SR
J Appl Toxicol; 2004; 24(4):261-8. PubMed ID: 15300713
[TBL] [Abstract][Full Text] [Related]
14. New generation of mucosal adjuvants for the induction of protective immunity.
Yuki Y; Kiyono H
Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
[TBL] [Abstract][Full Text] [Related]
15. Monophosphoryl lipid A analogues with varying 3-O-substitution: synthesis and potent adjuvant activity.
Jiang ZH; Budzynski WA; Qiu D; Yalamati D; Koganty RR
Carbohydr Res; 2007 May; 342(6):784-96. PubMed ID: 17300769
[TBL] [Abstract][Full Text] [Related]
16. Liposomes containing lipid A: an effective, safe, generic adjuvant system for synthetic vaccines.
Alving CR; Rao M; Steers NJ; Matyas GR; Mayorov AV
Expert Rev Vaccines; 2012 Jun; 11(6):733-44. PubMed ID: 22873129
[TBL] [Abstract][Full Text] [Related]
17. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy.
Baldrick P; Richardson D; Woroniecki SR; Lees B
J Appl Toxicol; 2007; 27(4):399-409. PubMed ID: 17299813
[TBL] [Abstract][Full Text] [Related]
18. Lactoferrin-monophosphoryl lipid A complex enhances immunity of mice to Plesiomonas shigelloides CNCTC 138/92.
Chodaczek G; Zimecki M; Lukasiewicz J; Lugowski C
Acta Biochim Pol; 2008; 55(1):91-6. PubMed ID: 18231655
[TBL] [Abstract][Full Text] [Related]
19. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses.
Puggioni F; Durham SR; Francis JN
Allergy; 2005 May; 60(5):678-84. PubMed ID: 15813815
[TBL] [Abstract][Full Text] [Related]
20. A new approach to vaccine adjuvants. Immunopotentiation by intracellular T-helper-like signals transmitted by loxoribine.
Goodman MG
Pharm Biotechnol; 1995; 6():581-609. PubMed ID: 7551237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
